James L M Ferrara
Overview
Explore the profile of James L M Ferrara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
6588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guisado D, Talware S, Wang X, Davis A, Fozilov E, Etra A, et al.
Gut
. 2025 Feb;
PMID: 39961646
Background: Treatment strategies for Crohn's disease (CD) suppress diverse inflammatory pathways but many patients remain refractory to treatment. Autologous haematopoietic stem cell transplantation (SCT) is an emerging therapy for medically...
2.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, et al.
Transplant Cell Ther
. 2024 Dec;
31(1):10.e1-10.e9.
PMID: 39667999
Background: The standard treatment for acute graft-vs-host disease (GVHD), a common complication following allogeneic hematopoietic cell transplant, remains prolonged courses of high dose corticosteroids. Previous attempts to decrease corticosteroid exposure...
3.
Rios C, Qayed M, Etra A, Reshef R, Newcomb R, Yuhasz N, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1061.e1-1061.e10.
PMID: 39222793
Acute graft-versus-host disease (GVHD) is a significant complication following hematopoietic stem cell transplantation (HCT). Although recent advancements in GVHD prophylaxis have resulted in successful HCT across HLA barriers and expanded...
4.
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, et al.
Blood
. 2024 Jul;
144(9):1010-1021.
PMID: 38968143
Acute graft-versus-host disease (GVHD) grading systems that use only clinical symptoms at treatment initiation such as the Minnesota risk identify standard and high-risk categories but lack a low-risk category suitable...
5.
Guisado D, Talware S, Wang X, Davis A, Fozilov E, Etra A, et al.
bioRxiv
. 2024 Jun;
PMID: 38895305
Background: Treatment strategies for Crohn's disease (CD) suppress diverse inflammatory pathways but many patients remain refractory to treatment. Autologous hematopoietic stem cell transplantation (SCT) has emerged as a therapy for...
6.
DeFilipp Z, Kim H, Spyrou N, Katsivelos N, Kowalyk S, Eng G, et al.
Blood Adv
. 2024 Apr;
8(13):3488-3496.
PMID: 38640197
The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic...
7.
Etra A, Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G, et al.
Blood Adv
. 2024 Apr;
8(12):3284-3292.
PMID: 38640195
Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of...
8.
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk F, et al.
Transplant Cell Ther
. 2024 Mar;
30(6):603.e1-603.e11.
PMID: 38548227
Acute graft versus host disease (GVHD) is a common and serious complication of allogeneic hematopoietic cell transplantation (HCT) in children but overall clinical grade at onset only modestly predicts response...
9.
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, et al.
Blood Adv
. 2024 Feb;
8(8):2047-2057.
PMID: 38324721
The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute...
10.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, et al.
Transplant Cell Ther
. 2024 Feb;
30(4):421-432.
PMID: 38320730
The overall response rate (ORR) 28 days after treatment has been adopted as the primary endpoint for clinical trials of acute graft versus host disease (GVHD). However, physicians often need...